EUVIMEDEUVIMED entdecken
Crossref

Emulating Target Trials to Address Immortal Time: Sequential Trial Emulation and the Clone-Censor-Weight Method

Toshiki FUKASAWA, Tomohiro SHINOZAKI

Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku · 2026 · 31 (1) · 31-45

DOI: 10.3820/jjpe.31.e3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku, 2026. Verfasst von Toshiki FUKASAWA und 1 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immortal time in observational studies arises when three core design components—eligibility determination (Telig), treatment assignment (Tassign), and the start of follow-up (time zero, T0)—are not temporally aligned, which can substantially distort estimates of treatment effects. Based on the target trial framework, this paper provides a structured overview of design options to avoid immortal time, centered on the principle of synchronizing these three elements at T0. We classify common observational scenarios into four types along two dimensions: (i) how often eligibility is met and (ii) whether treatment strategies can be distinguished at T0. We then discuss sequential trial emulation, which can improve statistical efficiency when eligibility is repeatedly satisfied, and the clone-censor-weight method, which can accommodate complex treatment strategies that include a grace period, illustrating each with applied examples. We also situate the new-user design and its variants, as well as conventional approaches to immortal time such as landmark and person-time analyses, by clarifying their theoretical connections to and departures from target trial emulation. The contribution of the approaches presented here extends beyond the technical avoidance of immortal time. Their central value lies in enabling researchers to formulate causal questions while preserving clinically meaningful treatment strategies that explicitly specify when treatment is initiated and how it is implemented in practice, rather than reshaping those questions to fit the constraints of traditional analytic methods. We hope that the systematic framework presented here will catalyze a paradigm shift in applied observational research and serve as a standard for evidence generation that supports clinical decision-making. : (Jpn J Pharmacoepidemiol 2026; 31 (1): 31‒45)

Zitieren

APA

FUKASAWA, T., & SHINOZAKI, T. (2026). Emulating Target Trials to Address Immortal Time: Sequential Trial Emulation and the Clone-Censor-Weight Method. Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku, 31(1), 31-45. https://doi.org/10.3820/jjpe.31.e3

Vancouver

FUKASAWA T, SHINOZAKI T. Emulating Target Trials to Address Immortal Time: Sequential Trial Emulation and the Clone-Censor-Weight Method. Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku. 2026;31(1):31-45. doi:10.3820/jjpe.31.e3

BibTeX
@article{FUKASAWA2026,
  author = {FUKASAWA, Toshiki and SHINOZAKI, Tomohiro},
  title = {Emulating Target Trials to Address Immortal Time: Sequential Trial Emulation and the Clone-Censor-Weight Method},
  journal = {Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku},
  year = {2026},
  volume = {31},
  number = {1},
  pages = {31--45},
  doi = {10.3820/jjpe.31.e3}
}
Kostenlos starten →